Bone Marrow Mesenchymal Stem Cells Inhibit Lipopolysaccharide-Induced Inflammatory Reactions in Macrophages and Endothelial Cells.
Bone Marrow Mesenchymal Stem Cells Inhibit Lipopolysaccharide-Induced Inflammatory Reactions in Macrophages and Endothelial Cells.
复制标题
骨髓间充质干细胞抑制脂多糖诱导的巨噬细胞和内皮细胞的炎症反应
DOI：
10.1155/2016/2631439
复制
发表时间：
2016
影响因子：
4.6
通讯作者：
Pan J
中科院分区：
文献类型：
--
作者：
Li D;Wang C;Chi C;Wang Y;Zhao J;Fang J;Pan J
背景资料。全身炎症反应综合征(SIRS)合并创伤可导致多器官功能障碍综合征(MODS)，甚至死亡。早期抑制炎症对于控制损害是必要的。骨髓间充质干细胞(BMSCs)作为一种新的治疗手段，在人和动物模型中被证明可以减少炎症反应。方法：研究方法。本研究采用免疫印迹、定量聚合酶链式反应和酶联免疫吸附试验检测骨髓间充质干细胞对脂多糖诱导的人脐静脉内皮细胞和肺泡巨噬细胞炎症的抑制作用。结果。结果表明，内毒素可引起肺泡巨噬细胞和人脐静脉内皮细胞的炎症反应，增加内皮细胞的通透性，上调Toll样受体2、TLR4、磷酸化p65的表达，下调IL 10的释放，促进肿瘤坏死因子α的释放。与骨髓间充质干细胞共培养可减弱脂多糖诱导的上述两种细胞类型的上述活性。结论。综上所述，我们的结果表明，BMSCs具有剂量依赖性地减轻脂多糖诱导的肺泡巨噬细胞和人脐静脉内皮细胞的炎症损伤。
Background. Systemic inflammatory response syndrome (SIRS) accompanied by trauma can lead to multiple organ dysfunction syndrome (MODS) and even death. Early inhibition of the inflammation is necessary for damage control. Bone marrow mesenchymal stem cells (BMSCs), as a novel therapy modality, have been shown to reduce inflammatory responses in human and animal models. Methods. In this study, we used Western blot, quantitative PCR, and enzyme-linked immunosorbent assay (ELISA) to assess the activity of BMSCs to suppress the inflammation induced by lipopolysaccharide (LPS) in human umbilical cord endothelial cells (HUVECs) and alveolar macrophages. Results. Our results demonstrated that LPS caused an inflammatory response in alveolar macrophages and HUVECs, increased permeability of HUVEC, upregulated expression of toll-like receptor (TLR) 2, TLR4, phosphorylated p65, downregulated release of IL10, and promoted release of TNF-α in both cells. Coculture with BMSCs attenuated all of these activities induced by LPS in the two tested cell types. Conclusions. Together, our results demonstrate that BMSCs dosage dependently attenuates the inflammation damage of alveolar macrophages and HUVECs induced by LPS.